T CELLS ENGINEERED TO EXPRESS A
DEFINED GAMMA DELTA RECEPTOR (TEGs)
Gadeta developed a new technology platform based on ground breaking discoveries by Prof. Dr. Jürgen Kuball at the University Medical Centre Utrecht (UMCU) in The Netherlands.
γδ Receptors display an enhanced anti-cancer reactivity based on selectively sensing metabolic changes in cancer cells resulting in a broad recognition of both hematological and solid tumors whilst leaving healthy tissue unharmed.
Marcu-Malina V. et al Blood 2011
The first description of the superiority of TEGs above conventional γδT cells.
KEY PUBLICATIONS
Sebestyen Z. et al Cell Reports 2016
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.
Development of an unbiased, genome-wide screening method that identified RhoB as a critical mediator of Vγ9Vδ2 TCR activation in tumor cells.
Scheper W. et al Leukemia 2013
GammadeltaT-cells elicited by CMV-reactivation after allo-SCT cross-recognize CMV and leukemia.
Elucidating a crucial role for γδT cells and the γδTCR in controlling leukemia relapse after allo-HSCT. This novel insight solves a long-standing riddle as to why less relapses are observed after CMV infection in the context of allo-HSCT.
Grunder C. et al Blood 2012
Discovery of the broad tumor recognition of TEGs and the CDR3-region as critical determinant